During what has been a rollercoaster-like pattern for more than a decade, market expectations for transcatheter mitral valve replacement (TMVR) devices are continuing to follow an upward trajectory in ...
Edwards Lifesciences recently exercised its option to acquire Innovalve Bio Medical, an early-stage transcatheter mitral valve replacement (TMVR) company. The company expects to pay about $300 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results